Indivior Stock Price, News & Analysis (LON:INDV)

GBX 380.22 -2.78 (-0.73 %)
(As of 02/19/2018 05:01 AM ET)
Previous CloseGBX 383
Today's RangeGBX 378.80 - GBX 383.70
52-Week RangeGBX 246.50 - GBX 436.60
Volume166,071 shs
Average Volume1.88 million shs
Market Capitalization£2.76 billion
P/E Ratio7,604.40
Dividend YieldN/A
BetaN/A

About Indivior (LON:INDV)

Indivior logoIndivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Receive INDV News and Ratings via Email

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorSpecialty & Advanced Pharmaceuticals
SymbolLON:INDV
CUSIPN/A
Phone+44-1753-217800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio7604.4
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.05
Net IncomeN/A
Net Margins18.18%
Return on EquityN/A
Return on Assets14.88%

Miscellaneous

EmployeesN/A
Outstanding Shares721,460,000

Indivior (LON:INDV) Frequently Asked Questions

What is Indivior's stock symbol?

Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV."

Where is Indivior's stock going? Where will Indivior's stock price be in 2018?

7 brokers have issued 12 month target prices for Indivior's shares. Their predictions range from GBX 395 to GBX 640. On average, they expect Indivior's share price to reach GBX 482.14 in the next year. View Analyst Ratings for Indivior.

Who are some of Indivior's key competitors?

Who are Indivior's key executives?

Indivior's management team includes the folowing people:

  • Howard Pien, Executive Chairman of the Board
  • Shaun Thaxter, Chief Executive Officer, Executive Director
  • Mark Crossley, Chief Financial Officer, Executive Director
  • Jon Fogle, Chief Human Resource Officer
  • Ingo Elfering, Chief Information Officer
  • Christian Heidbreder, Chief Scientific Officer
  • Kathryn Hudson, Company Secretary
  • Tatjana May, Non-Executive Director (Age 49)
  • A. Thomas McLellan Ph.D., Non-Executive Director
  • Daniel Tasse, Senior Independent Director (Age 57)

How do I buy Indivior stock?

Shares of Indivior and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Indivior's stock price today?

One share of Indivior stock can currently be purchased for approximately GBX 380.22.

How big of a company is Indivior?

Indivior has a market capitalization of £2.76 billion.

How can I contact Indivior?

Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800.


MarketBeat Community Rating for Indivior (INDV)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Indivior (LON:INDV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 482.14GBX 476.43GBX 448.14GBX 455.83

Indivior (LON:INDV) Consensus Price Target History

Price Target History for Indivior (LON:INDV)

Indivior (LON:INDV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/15/2018Numis SecuritiesReiterated RatingBuyGBX 640View Rating Details
1/26/2018Royal Bank of CanadaBoost Price TargetOutperformGBX 500 -> GBX 540View Rating Details
1/17/2018Jefferies GroupReiterated RatingBuyGBX 500View Rating Details
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 410View Rating Details
11/8/2017CitigroupUpgradeBuyGBX 280 -> GBX 490View Rating Details
9/15/2017Stifel NicolausReiterated RatingBuyGBX 400View Rating Details
2/23/2017Deutsche BankReiterated RatingBuyGBX 395View Rating Details
(Data available from 2/19/2016 forward)

Earnings

Earnings History for Indivior (LON:INDV)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Indivior (LON:INDV) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Indivior (LON:INDV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Indivior (LON INDV) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Indivior (LON:INDV)

Indivior (LON INDV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2017Lorna ParkerInsiderBuy1,231GBX 342£4,210.02
5/12/2016Tassé,DanielInsiderBuy3,903GBX 161£6,283.83
5/13/2015Daniel TasséInsiderBuy6,209GBX 229.28£14,236
3/27/2015Shaun ThaxterInsiderBuy20,000GBX 196£39,200
3/26/2015Shaun ThaxterInsiderBuy10,000GBX 197.17£19,717
2/16/2015Shaun ThaxterInsiderBuy35,000GBX 161.59£56,556.50
2/13/2015Cary ClaiborneInsiderBuy62,000GBX 166.24£103,068.80
2/12/2015Cary ClaiborneInsiderBuy23,780GBX 170£40,426
2/11/2015Shaun ThaxterInsiderBuy10,000GBX 163.36£16,336
(Data available from 1/1/2013 forward)

Headlines

Indivior (LON INDV) News Headlines

Source:
DateHeadline
Indivior (INDV) Receives "Buy" Rating from Numis SecuritiesIndivior (INDV) Receives "Buy" Rating from Numis Securities
www.americanbankingnews.com - February 17 at 9:22 PM
Indivior swings to loss despite revenue growthIndivior swings to loss despite revenue growth
www.marketwatch.com - February 15 at 4:34 PM
Indivior PLC (LON:INDV) Is Trading At A 26.32% Discount To Its Intrinsic ValueIndivior PLC (LON:INDV) Is Trading At A 26.32% Discount To Its Intrinsic Value
finance.yahoo.com - February 12 at 4:32 PM
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filersIndivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers
finance.yahoo.com - February 8 at 4:24 PM
Indivior expects boost from U.S. tax reformIndivior expects boost from U.S. tax reform
www.marketwatch.com - February 1 at 9:13 AM
Indivior (INDV) Price Target Increased to GBX 540 by Analysts at Royal Bank of CanadaIndivior (INDV) Price Target Increased to GBX 540 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - January 27 at 12:36 PM
Indivior PLC (INDV) Receives Consensus Rating of "Buy" from AnalystsIndivior PLC (INDV) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 26 at 3:24 PM
JP Morgan Healthcare Conference - London South East (blog)JP Morgan Healthcare Conference - London South East (blog)
www.lse.co.uk - January 5 at 3:47 PM
Indivior partners with Addex on addiction drugs - MarketWatchIndivior partners with Addex on addiction drugs - MarketWatch
www.marketwatch.com - January 5 at 3:47 PM
Indiviors Shaun Thaxter to Present at the 36th Annual JP Morgan Healthcare Conference on January 11th - PR Newswire (press release)Indivior's Shaun Thaxter to Present at the 36th Annual JP Morgan Healthcare Conference on January 11th - PR Newswire (press release)
www.prnewswire.com - January 5 at 3:47 PM
Addex Therapeutics: Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction TreatmentsAddex Therapeutics: Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments
www.finanznachrichten.de - January 4 at 3:45 PM
Addex To Get $330 Mln Potential Milestones In Licensing Deal With IndiviorAddex To Get $330 Mln Potential Milestones In Licensing Deal With Indivior
www.nasdaq.com - January 3 at 10:44 AM
Indivior partners with Addex on addiction drugsIndivior partners with Addex on addiction drugs
www.marketwatch.com - January 3 at 10:44 AM
Indivior PLC (INDV) Given Consensus Recommendation of "Buy" by BrokeragesIndivior PLC (INDV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 1 at 3:40 PM
What Should You Know About Indivior PLC’s (LON:INDV) Earnings Trajectory?What Should You Know About Indivior PLC’s (LON:INDV) Earnings Trajectory?
finance.yahoo.com - December 28 at 4:59 PM
Should You Be Tempted To Buy Indivior PLC (LON:INDV) At Its Current PE Ratio?Should You Be Tempted To Buy Indivior PLC (LON:INDV) At Its Current PE Ratio?
finance.yahoo.com - December 20 at 3:43 PM
Indivior Finance S.ar.l. -- Moodys affirms Indiviors ratings; stable outlookIndivior Finance S.ar.l. -- Moody's affirms Indivior's ratings; stable outlook
finance.yahoo.com - December 14 at 4:04 PM
DURECT (DRRX) Reports NDA Acceptance For Indiviors RBP-7000 Risperidone Monthly Depot - StreetInsider.comDURECT (DRRX) Reports NDA Acceptance For Indivior's RBP-7000 Risperidone Monthly Depot - StreetInsider.com
www.streetinsider.com - December 13 at 11:38 AM
What Are Analysts Saying About Indivior PLC’s (LSE:INDV) Growth?What Are Analysts Saying About Indivior PLC’s (LSE:INDV) Growth?
finance.yahoo.com - December 11 at 3:42 PM
FDA OKs Indivior opioid-use disorder treatmentFDA OKs Indivior opioid-use disorder treatment
www.marketwatch.com - December 1 at 6:27 PM
FDA Approves Indivior Opioid-use Disorder TreatmentFDA Approves Indivior Opioid-use Disorder Treatment
www.rttnews.com - December 1 at 6:27 PM
[$$] FDA Approves Monthly Injection for Opioid Addiction[$$] FDA Approves Monthly Injection for Opioid Addiction
finance.yahoo.com - December 1 at 6:27 PM
FDA Decisions In November: The Month In ReviewFDA Decisions In November: The Month In Review
feeds.benzinga.com - December 1 at 2:37 PM
Indiviors (INDV) Outperform Rating Reiterated at Royal Bank Of CanadaIndivior's (INDV) Outperform Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - December 1 at 6:46 AM
Indivior (INDV) Rating Reiterated by Morgan StanleyIndivior (INDV) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - December 1 at 6:43 AM
Indivior (INDV) Rating Reiterated by Numis SecuritiesIndivior (INDV) Rating Reiterated by Numis Securities
www.americanbankingnews.com - December 1 at 12:28 AM
FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use DisorderFDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder
www.prnewswire.com - November 30 at 9:48 PM
Indiviors Opioid Use Disorder Drug Inching Closer To FDA Approval...Indivior's Opioid Use Disorder Drug Inching Closer To FDA Approval...
www.rttnews.com - November 27 at 5:23 PM
Indivior PLC (INDV) Receives Average Rating of "Buy" from BrokeragesIndivior PLC (INDV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 5:58 PM
Morgan Stanley Raises Indivior PLC (INDV) Price Target to GBX 410Morgan Stanley Raises Indivior PLC (INDV) Price Target to GBX 410
www.americanbankingnews.com - November 9 at 7:04 AM
Indivior swings to profit on strong U.S. showingIndivior swings to profit on strong U.S. showing
www.marketwatch.com - November 4 at 2:20 AM
[$$] Investors Chronicle: LoknStore, BP, Indivior[$$] Investors Chronicle: Lok'nStore, BP, Indivior
finance.yahoo.com - November 4 at 2:20 AM
Indivior opioid addiction drug gets FDA nod - MarketWatchIndivior opioid addiction drug gets FDA nod - MarketWatch
www.marketwatch.com - November 3 at 9:56 AM
UKs Indivior posts profit compared with year-ago lossUK's Indivior posts profit compared with year-ago loss
finance.yahoo.com - November 3 at 9:56 AM
Edited Transcript of INDV.L earnings conference call or presentation 2-Nov-17 12:00pm GMTEdited Transcript of INDV.L earnings conference call or presentation 2-Nov-17 12:00pm GMT
finance.yahoo.com - November 3 at 9:56 AM
Indivior opioid addiction drug gets FDA nodIndivior opioid addiction drug gets FDA nod
www.marketwatch.com - November 2 at 2:22 AM
Indivior Plc – Value Analysis (LONDON:INDV) : November 1, 2017Indivior Plc – Value Analysis (LONDON:INDV) : November 1, 2017
finance.yahoo.com - November 2 at 2:22 AM
FDA Advisory Committees Recommend Approval of Indiviors RBP-6000 for the Treatment of Opioid Use Disorder - PR Newswire (press release)FDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder - PR Newswire (press release)
www.prnewswire.com - October 31 at 10:34 PM
Indivior Plc breached its 50 day moving average in a Bullish Manner : INDV-GB : October 31, 2017Indivior Plc breached its 50 day moving average in a Bullish Manner : INDV-GB : October 31, 2017
finance.yahoo.com - October 31 at 10:34 PM
FDA Advisory Committees Recommend Approval of Indiviors RBP-6000 for the Treatment of Opioid Use DisorderFDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder
finance.yahoo.com - October 31 at 10:34 PM
U.S. FDA panel backs approval for Indivior opioid addiction drugU.S. FDA panel backs approval for Indivior opioid addiction drug
finance.yahoo.com - October 31 at 10:34 PM
Numis Securities Ltd Reiterates "Buy" Rating for Indivior PLC (INDV)Numis Securities Ltd Reiterates "Buy" Rating for Indivior PLC (INDV)
www.americanbankingnews.com - October 30 at 8:22 AM
Numis Securities Ltd Reiterates Buy Rating for Indivior PLC (INDV)Numis Securities Ltd Reiterates Buy Rating for Indivior PLC (INDV)
www.americanbankingnews.com - October 21 at 6:40 PM
Indivior PLC (INDV) Receives Consensus Rating of "Buy" from BrokeragesIndivior PLC (INDV) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 18 at 9:04 PM
Indivior Submits NDA To FDA For RBP-7000, Signs Pact With DurectIndivior Submits NDA To FDA For RBP-7000, Signs Pact With Durect
www.rttnews.com - October 2 at 1:11 PM
Indivior files to sell schizophrenia drug in U.S.Indivior files to sell schizophrenia drug in U.S.
www.marketwatch.com - October 2 at 1:11 PM
Indivior PLC (INDV) Receives Average Rating of "Buy" from AnalystsIndivior PLC (INDV) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 23 at 6:54 PM
Why this beaten-up FTSE 100 dividend stock could be a bargainWhy this beaten-up FTSE 100 dividend stock could be a bargain
www.fool.co.uk - September 17 at 6:58 PM
Indivior Unit Files Lawsuits In U.S. To Protect SUBOXONE Film PatentIndivior Unit Files Lawsuits In U.S. To Protect SUBOXONE Film Patent
www.rttnews.com - September 16 at 7:05 PM
Indivior PLCs (INDV) Buy Rating Reiterated at Numis Securities LtdIndivior PLC's (INDV) Buy Rating Reiterated at Numis Securities Ltd
www.americanbankingnews.com - September 15 at 11:46 AM

SEC Filings

Indivior (LON:INDV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Indivior (LON INDV) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.